Xalatan
Xalatan is a medicine authorised by Swissmedic under authorisation number 53675. The authorisation holder is Viatris Pharma GmbH. The medicinal product code is Synthetic medicines and the dispensing category is B: Supplied only against a prescription which, at the prescriber's discretion, may be dispensed repeatedly. First authorisation was granted on 18 September 1996 and the authorisation is valid without a time limit. ATC code S01EE01 places the medicine in the group Ophthalmologicals.
| Authorisation number | 53675 |
|---|---|
| Name | Xalatan |
| Full name | Xalatan, Augentropfen |
| Authorisation holder | Viatris Pharma GmbH |
| Medicinal product code | Synthetic medicines |
| Dispensing category | B · Prescription only |
| ATC code | S01EE01 |
| First authorisation | 18 September 1996 |
| Authorisation validity | unlimited |
| No. | Name | Dispensing category | Authorisation date |
|---|---|---|---|
| 1 | Xalatan, Augentropfen | B | 18 September 1996 |
Scroll the table sideways
| Pack code | Quantity | Unit | ATC | IT code | Dispensing category |
|---|---|---|---|---|---|
| 18 | 1 x 2,5 | ml | S01EE01 | 11.09.0. | B |
| 26 | 3 x 2,5 | ml | S01EE01 | 11.09.0. | B |
Scroll the table sideways
Medicines in the same ATC group
Other medicines from this authorisation holder
Frequently asked questions
Is Xalatan authorised in Switzerland?
Yes. Xalatan is authorised by Swissmedic under authorisation number 53675, data as of 01 September 2026. The authorisation is valid without a time limit.
Which dispensing category does Xalatan have?
Xalatan is in dispensing category B. Supplied only against a prescription which, at the prescriber's discretion, may be dispensed repeatedly.
Who is the authorisation holder of Xalatan?
The authorisation holder is Viatris Pharma GmbH. The holder carries the legal responsibility for quality, safety and product information of the medicine in Switzerland.
Sources
Swissmedic data as of 01 September 2026. No medical advice. Independent directory, not affiliated with Swissmedic or the FOPH.